phrykt

Dogwood Therapeutics, Inc. (DWTX): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of DWTX were reported in the last 12 months. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

No DWTX insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

DWTX short interest

Low short interest. 0.3% of DWTX shares are sold short: about 1 share in 304. Over the last 12 reports the number of shares short went up 3%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 111,693 DWTX shares were sold short, 0.3% of the shares outstanding, up 79.0% from the report before. At the average daily volume of 67,836 shares, buying them all back would take about 1.6 trading days (days to cover).

Shares short, % of all shares

0.33%May 15Oct 300.37%

Days to cover

1.6May 15Oct 301.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026111,6930.33%+79%67,8361.6
Oct 15, 202662,4060.18%+60%76,0741.0
Sep 30, 202638,8950.11%-48%64,4511.0
Sep 15, 202674,2690.22%-17%67,2371.1
Aug 31, 202689,3980.26%+79%87,9271.0
Aug 14, 202649,9580.15%-32%50,5201.0
Jul 31, 202673,7900.22%+1%47,1391.6
Jul 15, 202673,0160.22%-24%101,9151.0
Jun 30, 202696,2540.29%+258%110,3111.0
Jun 15, 202626,9240.08%-59%70,1311.0
May 29, 202665,0850.19%-40%44,6671.5
May 15, 2026108,4180.32%-14%111,6401.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Dogwood Therapeutics company events

Dogwood Therapeutics filed 12 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Oct 19, 2026AgreementDogwood Therapeutics, Inc. entered into a Subscription Agreement with Sealbond Limited, pursuant to which the Company agreed to issue and sell 4,098,360 shares of common stock, par value $0.0001 per share, of the Company to Sealbond in a private placement. Filing
  3. Aug 13, 2026ResultsReleased financial results. Filing
  4. Jun 17, 2026VoteReported shareholder vote results. Filing
  5. May 14, 2026ResultsReleased financial results. Filing
  6. Mar 26, 2026AnnouncementShared information with investors. Filing
  7. Mar 18, 2026ResultsReleased financial results. Filing
  8. Mar 12, 2026VoteReported shareholder vote results. Filing
  9. Jan 20, 2026AnnouncementShared information with investors. Filing
  10. Jan 13, 2026AgreementDogwood Therapeutics, Inc., a Delaware corporation entered into a securities purchase agreement with a single institutional investor named therein pursuant to which the Company agreed to sell and issue in a registered direct offering to the Investor 2,338,948 shares of common stock, par value… Filing
  11. Nov 28, 2025AgreementDogwood Therapeutics, Inc., a Delaware corporation, entered into an Equity Distribution Agreement with Northland Securities, Inc. (trade name Northland Capital Markets), as sales agent, relating to the issuance and sale from time to time by the Company, through the Sales Agent, of shares of the… Filing
  12. Nov 21, 2025LeadershipDogwood Therapeutics, Inc. Second Amended and Restated Equity Incentive Plan. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Dogwood Therapeutics financials

Famous investors that hold DWTX

2 of the 50 well-known investors we track reported holding DWTX in their latest 13F filing. The largest position is Israel Englander's, worth $817K.

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026605,303$817K0.0%+77%
Ken Griffin · Citadel AdvisorsQ3 202649,748$67.2K0.0%+324%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named DWTX in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Armistice Capital, LLC13G/A7.7%
Nov 16, 2026Armistice Capital, LLC13G/A7.7%
Oct 27, 2026Sealbond Limited13D/A67.8%
Oct 27, 2026Sealbond Limited13D/A67.8%
Oct 21, 2026Sealbond Limited13D/A63.9%
Oct 21, 2026Sealbond Limited13D/A63.9%

Questions about Dogwood Therapeutics, Inc. (DWTX) stock

Are DWTX insiders buying or selling?

No DWTX insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in DWTX?

As of Oct 30, 2026, 111,693 DWTX shares were sold short, 0.3% of the shares outstanding, up 79.0% from the report before. At the average daily volume of 67,836 shares, buying them all back would take about 1.6 trading days (days to cover). See the history.

Which famous investors hold DWTX?

2 of the 50 well-known investors we track reported DWTX in their latest 13F filing, including Israel Englander, Ken Griffin. The largest position is worth $817K. See all holders.

Executive pay

Dogwood Therapeutics's chief executive was paid a total of $3.3M for the year ended Dec 31, 2025, up 280% from $881K the year before. In the last 12 months, Dogwood Therapeutics's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$3.3MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$2.6MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.3MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.